FDA authorized phase 1 trial of ImmunityBioﾒs novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
Brazilian Health Regulatory Agency authorized Sorrento’s phase 2 clinical trial of Abivertinib in COVID-19 patients
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
COVID-19 vaccine with Dynavaxﾒs CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
Biotechnology | COVID-19 | NIH | Therapeutics
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
FDA awarded grants to fund clinical trials to advance development of products for treatment of rare diseases
On Oct. 8, 2020, the FDA announced that it had awarded six new clinical trial research grants to…
Emergent BioSolutionsﾒ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
Lilly updated progress of SARS-CoV-2 neutralizing antibody programs
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ﾖ including interim…
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services announced funding of a patch that…
AIM ImmunoTech announced approval to enroll COVID-19 ‘long haulers’ in AMP-511 ME/CFS clinical trial of Ampligen
On Oct. 6, 2020, AIM ImmunoTech announced that it had received Institutional Review Board approval for the expansion…
BioNTech and Pfizer initiated a rolling submission to EMA for SARS-CoV-2 vaccine candidate BNT162b2
On Oct. 6, 2020, Pfizer and BioNTech announced initiation of a rolling submission to the European Medicines Agency…
COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
On Oct. 2, 2020, AstraZeneca announced the phase I/II clinical trial for the COVID-19 vaccine AZD1222 had resumed…
Hydroxychloroquine showed no benefit in COVID-19 prevention
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
CureVac Initiated phase 2a clinical trial of COVID-19 vaccine candidate
On Sept. 29, 2020, CureVac announced that the first participant has been dosed in a Phase 2a clinical…
Windtree announced FDA acceptance of IND application for phase 2 clinical trial studying KL4 Surfactant in acute lung injury in adults with COVID-19
On Sept. 29, 2020, Windtree Therapeutics announced that FDA had accepted its Investigational New Drug application for a…
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
Fourth large-scale COVID-19 vaccine trial began in the United States
On Sept. 23, 2020, a fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019…
Sinovacﾒs Coronavacﾙ, SARS-CoV-2 vaccine, inactivated, announced approval for phase I/II clinical trial in adolescents and children
On Sept. 23, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences,…
NIH expanded clinical trials to test convalescent plasma against COVID-19
On Sept. 22, 2020, the NIH annunced that two randomized, placebo-controlled clinical trials expanded enrollment to further evaluate…
Sinovac commenced phase III clinical trials for COVID-19 vaccine candidate in Turkey
On Sept. 22, 2020, Sinovac Biotech announced that it had recently commenced phase III clinical trials for its…
Serum Institute initiated manufacturing of Codagenix’s intranasal live-attenuated COVID-19 vaccine candidate
On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s…
Lilly announced proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
On Sept. 16, 2020, Eli Lilly announced proof of concept data from an interim analysis of the BLAZE-1…